Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001576885-25-000082
Filing Date
2025-06-05
Accepted
2025-06-05 16:59:03
Documents
1
Period of Report
2025-06-04

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1749157011.html 4  
1 FORM 4 wk-form4_1749157011.xml 4 5756
  Complete submission text file 0001576885-25-000082.txt   7358
Mailing Address 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465
Business Address 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465 617-344-4190
Acumen Pharmaceuticals, Inc. (Issuer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ACUMEN PHARMACEUTICALS, INC. 427 PARK STREET CHARLOTTESVILLE VA 22902
Business Address
Stalfort John A III (Reporting) CIK: 0001709418 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40551 | Film No.: 251027906